Peregrine Pharma (PPHM) Tops Q1 EPS by 6c, Beats on Revenues

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/6/2026

1. PTC
2. NVDA
3. PCVX
4. META
5. MSFT
6. SPY
7. GOOGL
8. GMAB
9. USO
10. AMD

Go back to Peregrine Pharma (PPHM) Tops Q1 EPS by 6c, Beats on Revenues

Peregrine Pharma (PPHM) Reports First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combination in Patients with Newly Diagnosed Glioblastoma

September 7, 2017 8:14 AM EDT

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced dosing of the first patient in a Phase II clinical trial evaluating the combination of bavituximab, temozolomide, and radiation therapy in patients with newly diagnosed glioblastoma. Elizabeth R. Gerstner, MD, at Massachusetts General Hospital Cancer Center, is the primary investigator for the trial, which is one of three bavituximab clinical studies being funded by the National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) through a grant provided by Peregrine.

The single group, interventional Phase II trial will enroll approximately 36 patients with newly diagnosed... More